Molecular characterization and expression of DERL1 in bovine ovarian follicles and corpora lutea by Ndiaye, Kalidou et al.
RESEARCH Open Access
Molecular characterization and expression of
DERL1 in bovine ovarian follicles and
corpora lutea
Kalidou Ndiaye
1,2,4*, Jacques G Lussier
3, Joy L Pate
1,5
Abstract
The endoplasmic reticulum (ER) is a major site of protein synthesis and facilitates the folding and assembly of
newly synthesized proteins. Misfolded proteins are retrotranslocated across the ER membrane and destroyed at the
proteasome. DERL1 is an important protein involved in the retrotranslocation and degradation of a subset of mis-
folded proteins from the ER. We characterized a 2617 bp cDNA from bovine granulosa cells that corresponded to
bovine DERL1. Two transcripts of 3 and 2.6 kb were detected by Northern blot analysis, and showed variations in
expression among tissues. During follicular development, DERL1 expression was greater in day 5 dominant follicles
compared to small follicles, ovulatory follicles, or corpus luteum (CL). Within the CL, DERL1 mRNA expression was
intermediate in midcycle, and lowest in late cycle as compared to early in the estrous cycle. Western blot analyses
demonstrated the presence of DERL1 in the bovine CL at days 5, 11, and 18 of the estrous cycle. Co-immunopreci-
pitation using luteal tissues showed that DERL1 interacts with class I MHC but not with VIMP or p97 ATPase. The
interaction between DERL1 and MHC I suggests that, in the CL, DERL1 may regulate the integrity of MHC I mole-
cules that are transported to the ER membrane. Furthermore, the greater expression of DERL1 mRNA is associated
with the active follicular development and early luteal stages, suggesting a role of DERL1 in tissue remodeling
events and maintenance of function in reproductive tissues.
Background
The endoplasmic reticulum (ER) is the first compart-
ment of the secretory pathway and is a processing sta-
tion for secreted and transmembrane proteins. The
primary function of the ER is to assist newly synthesized
proteins to refold into native conformation. To achieve
correct folding and maturation, secreted proteins must
translocate into the ER to undergo several post-transla-
tional modifications, including glycosylation and disul-
fide bonding [1]. Proteins that fail to fold properly in
the ER are recognized by the quality control machinery
and transferred from the ER into the cytosol to the ubi-
quitin-proteasome system in a process called retrotran-
slocation or dislocation [2]. The ER-associated
degradation (ERAD) machinery serves as one part of the
adaptive cellular program to destroy the potentially
toxic accumulation of misfolded proteins. A dysfunction
in the ERAD pathway causes human diseases [3] while
many viral proteins can hijack this pathway to evade
detection by the immune system [4].
This latter phenomenon is used by the human cyto-
megalovirus (HCMV) to eliminate class I major histo-
compatibility complex (MHC I) molecules to distract
cytotoxic T cells from destroying infected cells [5]. The
HCMV encodes the glycoproteins US2 and US11 that
induce retrotanslocation of newly synthesized class I
heavy chains [6]. The HCMV US2 and US11 proteins
utilize the normal ER quality control process to elimi-
n a t ec l a s sIh e a v yc h a i n si nas i m i l a rm a n n e ra sm i s -
folded or damaged ER proteins. The ERAD of class I
MHC heavy chain by HCMV-encoded US11 involves
DERL1, a mammalian ER membrane protein, homolog
of Der1p in Saccharomyces cerevisiae that is essential for
the relocation of misfolded proteins from the ER lumen
into the cytosol [7,8]. This action of DERL1 is per-
formed in concert with the ATPase p97/Valosin-con-
taining protein (VCP) that forms a complex with DERL1
[7,8] after being recruited by the VCP-interacting
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DERL1 [8].
The expressions of class I and class II MHC molecules
have been demonstrated in the corpus luteum (CL)
where they may function to regulate T lymphocyte acti-
vation, thus controlling the production of cytokines
[9-13]. The CL is a very heterogeneous population of
cells that becomes rapidly organized into a functional
unit. These diverse cells communicate both directly and
through paracrine mediators to facilitate the steroido-
genic function and the transient nature of the CL. The
CL also contains nonsteroidogenic cells, including
endothelial cells, fibroblasts, and immune cells that have
ar o l ei nl u t e a lf u n c t i o nb yc ommunicating with steroi-
dogenic cells through the paracrine signaling molecules
they produce and through direct cell contacts [14,15].
The MHC molecule-dependent interaction between
luteal cells and T cells is one form of direct cell-cell sig-
naling that may serve to activate resident immune cells
[16]. An association between MHC proteins and the
ERAD proteins in reproductive tissues has not been pre-
viously investigated. Thus, studying the link between
class I MHC and DERL1 in the CL may contribute to
understanding the control of luteal function.
There has been significant interest in the role of
DERL1 in the ER quality control machinery. However,
nothing is known about the expression of DERL1, its
regulation and physiological relevance in reproductive
tissues, such as the ovary. In this study, the expression
of DERL1 in bovine granulosa and luteal cells, and its
regulation at different stages of follicular growth and
corpora lutea development were analyzed. Using normal
luteal tissue extracts, putative interactions of DERL1
w i t hM H CI ,p 9 7A T P a s e ,a n dV I M Pw e r ea l s o
investigated.
Methods
Animal model for follicle collection
The regulation of DERL1 mRNA expression during folli-
cular development and ovulation was studied using
in vivo models as previously characterized [17]. Briefly,
estrous cycles of normally cyclic crossbred heifers were
synchronized with one injection of prostaglandin F2
alpha (PGF2a; 25 mg, im; Lutalyse, Upjohn, Kalamazoo,
MI) given in the presence of a CL. Ovarian follicular
development was monitored by daily transrectal ultraso-
nography. Following estrous synchronization, heifers
were randomly assigned to the dominant follicle group
(DF, n = 4), or the ovulatory, hCG-induced follicle
group (OF, n = 4). Immediately following ovariectomy,
granulosa cells (GC) were collected separately from indi-
vidual DF or OF as described previously [17], and stored
at -70°C. Additionally, GC were collected from 2-4 mm
small follicles (SF) obtained from slaughterhouse ovaries,
and a total of three pools of 10-20 SF was prepared.
C o r p o r al u t e aa td a y5o ft h ee s t r o u sc y c l ew e r e
obtained by ovariectomy and were dissected from the
ovarian stroma, frozen in liqu i dn i t r o g e n ,a n ds t o r e da t
-70°C until RNA was extracted. The Animal Ethics
Committee of the Faculty of Veterinary Medicine of the
University of Montreal approved all animal procedures.
Corpora lutea removal
Corpora lutea were collected transvaginally from cyclic
cows at early (day 5) mid (day 11) and late (day 18)
luteal phase of the estrous cycle (day of estrus = day 0)
and at 1, 4, 8, and 12 hours after a 25-mg injection of
PGF2a (Lutalyse; Upjohn, Kalamazoo, MI) in the midlu-
teal phase to induce luteal regression. Total RNA was
extracted from luteal tissues to quantify DERL1 mRNA
concentrations by real time-quantitative PCR. Corpora
lutea collection was performed at the Ohio State Uni-
versity and handling of animals and surgical procedures
were conducted according to protocols approved by the
Institutional Laboratory Animal Care and Use Commit-
tee of the Ohio State University.
Cloning of bovine DERL1
The DERL1 cDNA was cloned from a bovine cDNA
library prepared with polyA
+ mRNA isolated from gran-
ulosa cells of dominant follicles at day 5 of the estrous
cycle. The cDNA library was constructed in lambda Zap
Express vector (Stratagene, La Jolla, CA) by unidirec-
tional cloning of cDNAs as described [18]. Following in
vivo excision of pBluescript phagemids containing the
cloned cDNA insert with the Ex-Assist/XLOLR system
(Stratagene), single bacterial colonies were picked and
their phagemid content were purified by mini-prep
(Qiagen, Mississauga, ON). The cDNA inserts were ana-
lyzed by sequencing, and sequences were compared by
BLAST in GenBank database. Alignment of deduced
amino acid sequences of bovine DERL1 protein with
putative homologs from other organisms was performed
using the ClustalW2 analysis software (EMBL-EBI,
Hinxton, Cambridge, UK). DERL1 cDNA was entirely
characterized by sequencing on an ABI Prism 310
(Applied BioSystem).
RNA isolation and northern blot analysis
Various bovine tissues were obtained from a local
slaughterhouse and RNA was extracted in lysis buffer
(for 500 ml buffer: 4 M guanidium isothiocyanate,
2.5 ml Na-N-laurylsarcosine, 25 mM Na-citrate, pH 7),
and sedimented, following centrifugation on a cesium
chloride cushion as described [19]. The concentration of
total RNA was quantified by measurement of optical
density at 260 nm, and RNA integrity was evaluated by
visualizing the 28 S and 18 S ribosomal RNA bands
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dehyde denaturing 1% agarose gel with ethidium bro-
mide. Total RNA (20 μg/tissue) were size-fractionated
on a 0.66 M formaldehyde, 1% agarose gel, transfered by
capillarity to a nylon membrane (Hybond-N; Amersham
Pharmacia Biotech), and UV-treated (150 mJ) as
described [20]. The bovine DERL1 cDNA was used to
generate a radioactive probe incorporating [a
32P]-dCTP
(NEN Life Sciences, Boston, MA) that was used to
hybridize Northern blots as described [19].
Alternative splicing analysis of bovine DERL1
Analysis for the presence of putative alternative splicing
variants for bovine DERL1 mRNA was performed by RT-
PCR using total RNA from bovine CL. The first step con-
sisted of a reverse transcription reaction performed with
1 μg of total RNA using the M-MLV Reverse Transcrip-
tase (Promega) following the manufacturer’sp r o t o c o l .
The second step consisted of a PCR amplification with
specific primers (foward: 5′-ATGTCGGACATCGGG-
GACTGG-3′;r e v e r s e :5 ′-CTGGTCCCCGAGCCGA
AAGC-3′) located respectively at the start codon and
stop codon of the DERL1 open reading frame (ORF)
amplifying the entire ORF of 754 bp in a 35 cycle PCR
reaction. The PCR products were analyzed for size and
specificity using the Agilent DNA 1000 kit on the Agilent
2100 BioAnalyzer (Agilent Technologies).
Semi-quantitative RT-PCR
Expression of DERL1 mRNA during follicular develop-
ment was analyzed by semi-quantitative RT-PCR. Total
RNA was extracted from bovine granulosa cells (GC)
collected from 2-4 mm small follicles (SF), dominant
follicles at day 5 of the estrous cycle (DF), ovulatory fol-
licles 24 hours after an injection of hCG (OF), and from
d a y5c o r p o r al u t e a( C L ) .DERL1 PCR primers were as
follows: (forward: 5′-TATCGCTTCCAGATTTGGAGG-
3′;r e v e r s e :5 ′-GAATCCAAGGATAACCCAAGG-3′).
The number of cycles was limited and optimized for
analysis of DERL1 mRNA expression. PCR reaction pro-
ducts were separated on a 2% TAE-agarose gel with
ethidium bromide, visualized by UV light, digitized and
analyzed by densitometry using ImageQuant software
(Amersham Pharmacia Biotechniques). GAPDH was
used as a control gene, and specific signals of DERL1
were normalized with corresponding GAPDH signals.
qPCR analysis
Total RNA was extracted from luteal tissues using Tri-
zol reagent as described [15], quantified using the Nano-
drop spectrophotometer (Thermo Scientific), and treated
with RNase-free DNase I (Roche Molecular Biochem-
icals) to eliminate genomic DNA contamination. qPCR
was used to detect and quantify DERL1 mRNA.
Oligonucleotide primers specific for DERL1 transcript,
described in the semi-quantitative RT-PCR section, were
used to amplify DERL1 cDNA. Ribosomal protein L19
(RPL19) cDNA fragment was amplified as a constitu-
tively expressed gene with the following primers (for-
ward: 5′-ATCGATCGCCACATGTATCA-3′; reverse: 5′-
GCGTGCTTCCTTGGTCTTAG-3′). Total RNA (1 μg)
was reverse transcribed using the iScript cDNA Synth-
esis Kit (Bio-Rad Laboratories) according to the protocol
of the manufacturer. Following the reverse transcription
reaction, quantitative PCR was performed on the MJ
Research Opticon 2 (Bio-Rad Laboratories) as described
[15] using the iQSYBR Green Supermix (Bio-Rad
Laboratories). Homologous standard curve prepared
from purified DERL1 cDNA PCR product was used to
calculate the relative steady-state concentrations of
DERL1 mRNA in triplicate wells for each sample. The
PCR amplification products were electrophoretically
separated on 1.5% agarose gels and visualized with ethi-
dium bromide. For initial validation, the specific band
corresponding to the size of the expected DERL1 cDNA
fragment was cut and purified using the QIAquick Gel
Extraction Kit (Qiagen Sciences) for sequence confirma-
tion. A control sample that was not reverse transcribed
was used to confirm that the product obtained was not
amplified from genomic DNA.
Protein extraction and immunoblotting
Proteins were extracted from luteal tissues at days 5, 11,
and 18 of the estrous cycle using the CelLytic MT Cell
Lysis Reagent (Sigma-Aldrich Biotechnology) in the pre-
sence of the protease inhibitor cocktail (Sigma-Aldrich
Biotechnology) following the manufacturer’sp r o t o c o l .
Proteins were quantified according to the method of
Bradford [21] (Bio-Rad Protein Assay, Bio-Rad Labora-
tories). Protein samples (75 μg) were subjected to elec-
trophoresis on a 12% SDS-polyacrylamide gel, and the
separated proteins were blotted onto polyvinylidene
difluoride membranes (PVDF; Hybond-P, Amersham
Pharmacia Biotech). Western blot analyses were per-
formed exactly as described [15] using a polyclonal rab-
bit anti-DERL1 antibody (NB100-447SS; Novus
Biologicals), raised against a synthetic peptide corre-
sponding to amino acid residues 150-250 of human
DERL1 at a final concentration of 0.5 μg/ml. Mem-
branes were then washed as described [15] and incu-
bated with the horseradish peroxidase-labeled anti-
rabbit secondary antibody (Amersham Biosciences) at a
dilution of 1:20 000. The antigen-antibody complex was
visualized using the enhanced chemiluminescence sys-
tem (ECL Western Blotting Analysis System; Amersham
Biosciences) following the manufacturer’sp r o t o c o l .
Membranes were exposed to Kodak Biomax light films
(Kodak), and the films were developed in the SRX-101A
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tein bands were analyzed by densitometry using the
Kodak Image Station 4000R software (Eastman Kodak
Co.). Beta actin was used as an internal control to verify
the integrity of proteins in the samples and specific sig-
nals of DERL1 were normalized with corresponding beta
actin signals.
Co-immunoprecipitation
Protein samples were obtained from luteal tissues as
described above. Immunoprecipitation of DERL1 was
performed following the protocol as described [22]. Pro-
tein lysates (100 μg) were first incubated with 100 μlo f
S. aureus Cowan I (Pansorbin, Calbiochem) saturated
with normal rabbit serum and 50 μl of Sepharose CL-4B
(Amersham Pharmacia Biotech). After an overnight
incubation at 4°C with continuous gentle rocking fol-
lowed by centrifugation (10,600 g, 15 min, 4°C), the
supernatant was collected and incubated with 15 μlo f
specific anti-DERL1 antibodies with rocking for 2 hours
at 4°C. The antigen-antibody complex was precipitated
by the addition of 80 μl of protein A Sepharose CL-4B
(Amersham Pharmacia Biotech) for 1 hour at 4°C with
rocking followed by centrifugation (10,600 g, 1 min, 4°
C) to pellet the complex. Supernatants were collected at
this point and stored at -70°C for further analysis. The
pelleted precipitates containing DERL1 and potential
bound proteins were washed 3 times in lysis buffer con-
taining 1% Nonidet-P40. Both precipitate and corre-
sponding supernatant samples were heated at 90°C for 5
min in the presence of Laemmli loading buffer and
separated on SDS-polyacrylamide gel alongside molecu-
lar weight markers (Bio-Rad Laboratories). Proteins
were transferred onto PVDF membranes and blotted
separately with specific antibodies against class I MHC
(H17A; VMRD), VIMP (V6639; Sigma), and p97
(PRO65278; Research Diagnostics Inc.). Additional anti-
DERL1 antibodies were obtained from Sigma (D4443) in
order to confirm the presence of DERL1 in the
precipitates.
Statistical analysis
For the data from semi-quantitative PCR experiments,
gene-specific signals were normalized with correspond-
ing GAPDH signals for each sample. Homogeneity of
variance among follicular groups and CL was verified by
O’Brien and Brown-Forsythe tests. Corrected values of
gene-specific mRNA were compared by one-way
ANOVA in GC obtained from bovine follicles collected
at different developmental stages or CL. When ANOVA
showed significant differences, Tukey-Kramer multiple
comparisons was used to determine differences at p <
0.05. The same statistical procedure was used for
the western blot data with specific DERL1 signals
normalized with corresponding beta actin signals for
each sampling day. All other statistical analyses were
performed using the covariate analysis within the mixed
model of SAS (SAS Inst. Inc., Cary, NC) with RPL19 as
the covariate. Data were presented as least-square
means ± SEM and differences were considered signifi-
cant at p < 0.05.
Results
Cloning of bovine DERL1
The cDNA of DERL1 was cloned from bovine granulosa
cells (GC) of day 5 dominant follicles and characterized
by sequencing. The cDNA of DERL1 is 2617 bp in
length and encodes a hydrophobic protein of about 28.8
kDa containing 251 amino acid residues (GenBank:
AF279909). Amino acid analysis indicated that DERL1
presents four putative transmembrane domains located
between amino acid residues F
19-S
35,L
99-A
115,L
120-L
136,
and L
155-I
171, a feature of membrane protein. Sequence
comparison showed orthologous proteins from human
(GenBank accession number: NP_077271), pig
(XP_001928865), mouse (NP_077169), chicken
(NP_001006350), and frog (NP_001085401) that were,
respectively, 99, 99, 97, 90, and 86% identical to bovine
DERL1 (AF279909).
DERL1 mRNA expression and regulation during follicular
development
The expression of DERL1 mRNA was first analyzed via
Northern blot using several bovine tissues. Two tran-
scripts of DERL1 were detected at 3 kb and 2.6 kb (Fig.
1). DERL1 mRNA expression was observed in all tissues
analyzed, with variable intensities among tissues. The
Figure 1 Analysis of DERL1 mRNA expression in bovine tissues
by Northern blot. Two transcripts of 3 and 2.6 kb corresponding
to bovine DERL1 were observed and showed a variable pattern of
expression among tissues.
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lung and uterus, and was moderate in other tissues
including the CL. To verify possible alternative splicing
of DERL1 mRNA, PCR experiments amplifying the
entire open reading frame of DERL1 were performed
and demonstrated a single product (Fig. 2). No amplifi-
cation was observed in the control (without reverse
transcriptase enzyme) (Fig. 2) showing that the product
a m p l i f i e di sn o tf r o mg e n o m i cD N A .T h i sr e s u l ts u g -
gests that one protein is encoded from the mRNA and
that the two transcripts observed by Northern blot
might differ at their 3′-untranslated region. This differ-
ence could potentially mean a different control of the
stability of DERL1 mRNA.
The regulation of DERL1 mRNA during follicular
development was analyzed using semi-quantitative RT-
PCR. Greater expression of DERL1 was observed in
granulosa cells obtained from day 5 dominant follicles
(D5) compared to small follicles (SF), ovulatory follicles
(OF), and day 5 corpus luteum (CL) (p < 0.05; Fig. 3).
There was no difference in DERL1 mRNA among SF,
O F ,a n dC L( F i g .3 ) .GAPDH used as control gene was
not different among groups (p < 0.43).
DERL1 mRNA expression in bovine corpus luteum
RT-qPCR experiments using total RNA from luteal tis-
sues showed that steady state concentration of DERL1
mRNA was intermediate in midcycle (day 11, p =
0.064), and lowest in late cycle (day 18, p < 0.05) as
compared to early in the estrous cycle (day 5) (Fig. 4A).
In addition, DERL1 in day 11 CL was greater than in
day 18 CL (p < 0.05). Injection of PGF2a during the
midcycle induced a transient increase of DERL1 mRNA
in the CL after 8 hours (p = 0.065) followed by a slight
decrease at 12 hours post PGF2a (p = 0.081), compared
to day 11 CL (Fig. 4B). Additionally, DERL1 mRNA was
greater at 8 hours post PGF2a than at 1 hour and at
12 hours (p < 0.05; Fig. 4B).
DERL1 protein expression
In order to analyze the expression of DERL1 protein in
the CL, western blot analyses were performed and
demonstrated the presence of DERL1 in luteal tissues
from days 5, 11, and 18 of the estrous cycle (Fig. 5).
Similar to the mRNA, DERL1 protein expression was
greater in day 5 CL as compared to day 18 CL. Beta
actin used as the control protein did not show any var-
iation throughout the estrous cycle.
To determine if DERL1 interacts with class I MHC,
VIMP, or p97 ATPase, immunoprecipitation was per-
formed using protein lysate from luteal tissues with
anti-DERL1 antibodies from Novus Biologicals (NB100-
447SS) followed by western blotting and incubation with
various antibodies. Incubation with anti-DERL1
Figure 2 Analysis of alternative splicing of DERL1 mRNA. The specific DERL1 PCR product corresponding to the entire open reading frame is
represented by a single DERL1 PCR product; the sample without RT enzyme control shows that the specific DERL1 product amplified is not from
genomic DNA.
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DERL1 in the control sample from day 5 CL at the pre-
dicted molecular weight of about 28 kDa, and a second
band was observed at around 75 kDa in the precipated
samples from days 5, 11, and 18 of the estrous cycle
(Fig. 6A1) representing DERL1 and an interacting pro-
tein. Class I MHC antibodies used with the same preci-
pitates on a separate blot recognized a band of about 73
kDa (Fig. 6A2, top panel). To verify that class I MHC
did not bind to protein A used for precipitation, class I
MHC antibodies were incubated with blots from a mix-
ture containing only protein A with an aliquot of pro-
tein lysate, in the absence of DERL1 antibodies. This
experiment showed no binding of protein A to class I
MHC (Fig. 6A2, bottom panel), confirming that the pre-
s e n c eo fc l a s sIM H Ci nt h ep r e c i p i t a t ei sd u et oi t s
interaction with DERL1. Furthermore, the size of the
band observed in the precipitates using both anti-
DERL1 and anti-MHC I indicates that it is a result of
the interaction between DERL1 and MHC I. Finally,
MHC I protein was absent in the supernatant collected
after precipitation with anti-DERL1 antibodies and pro-
tein A (Fig. 6B1). In contrast, there was no interaction
of DERL1 with VIMP or p97 in the CL at any day of
the estrous cycle (Fig. 6A3, A4). However, both VIMP
and p97 were detected in the supernatant using, respec-
tively, specific anti-VIMP and anti-p97 antibodies
(Fig. 6B2, B3). Two bands of around 21 kDa and 49 kDa
were observed for VIMP in the supernatant (Fig. 6B2).
Discussion
These results provide support for a physiologically rele-
vant role for DERL1 in the ovary. First, the greatest
expression of DERL1 is associated with active ovarian
follicular growth, suggesting a role of DERL1 in develop-
ing follicles. The preovulatory LH surge induces several
changes in different compartments of the ovarian follicle
as it triggers ovulation, maturation of the cumulus
oocyte complex, and luteiniza t i o n[ 2 3 - 2 6 ] .I no v u l a t o r y
follicles, DERL1 decreased compared to dominant folli-
cles in our in vivo study. Following the comparison of
its mRNA profile in different bovine tissues by Northern
blot analysis, we hypothesized that DERL1 mRNA in
granulosa cells would vary in relation to follicular devel-
opment. Indeed, we have shown that DERL1 mRNA in
granulosa cells is regulated depending on the develop-
mental stage of the follicle. Increased expression of
DERL1 in dominant follicles and early CL might contri-
bute to protect granulosa cells against apoptosis and/or
developmental stresses during follicular or luteal growth.
Similarly, recent data in breast cancer cells showed that
DERL1 expression is increased by ER stress while
DERL1 knockdown resulted in decreased development
of cancer cells [27]. The latter study demonstrated that
DERL1 expression might be induced by stress inducers
in breast cancer cell lines and suggested that DERL1
could protect cancer cells against ER stress-induced
apoptosis [27]. These observations support a crucial role
of DERL1 for survival of rapidly growing cells within
normal tissues such as granulosa cells or within tumori-
genic tissues.
Additional evidence for the physiological significance
of DERL1 in the ovary is the differential expression of
DERL1 mRNA and protein during the luteal phase, and
the physical interaction of DERL1 protein with class I
MHC in freshly collected luteal tissues. No report is
available regarding DERL1 expression and regulation in
the CL. We demonstrated a link between DERL1
expression and the early stages of the functional CL.
Following ovulation, the luteinization process is realized
under intense tissue remodeling and organization. This
Figure 3 Analysis of DERL1 mRNA expression during follicular
development by semi-quantitative RT-PCR. The control gene
was GAPDH and showed no significant differences in mRNA
expression among the different groups. The DERL1 PCR signals were
normalized with their corresponding GAPDH signals, and the results
are presented as a relative change in ratio among groups. Different
letters denote samples that differed significantly (p < 0.05) when
Tukey-Kramer multiple comparison tests were performed to
compare group means. Data are presented as means ± SEM. DF =
dominant follicles (n = 4); OF = ovulatory follicles (n = 4); SF = 2-4
mm small follicles (n = 3); CL = corpus luteum collected on day 5
of the estrous cycle (n = 3).
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factors. The greatest expression of DERL1 early in this
process is in accordance with its putative role in the
quality control machinery of newly synthesized proteins.
Toward the end of the estrous cycle, DERL1 mRNA and
protein decreased significantly, suggesting that DERL1
might be required for the maintenance of a functional
CL. Analysis of progesterone (P4) concentrations showed
t h a tt h eC Lu s e da td a y1 8w e r en o tr e g r e s s i n gf u r t h e r
supporting that the decrease in DERL1 expression was a
physiological event.
The exact role of DERL1 in the ovary is unknown.
However, as previously hypothesized for other systems
[7,8], DERL1 proteins may form a channel by oligomeri-
zation or association with other factors, and are required
for protein degradation associated with the ER. Also, it
has been suggested that p97 ATPase participates in a
complex with DERL1 and that, in this complex, p97
ATPase provides the energy for dislocation [28]. In the
CL, we did not find any interaction between DERL1 and
p97. This may be because this interaction is triggered by
a specific event in the cell such as ER stress due to
accumulation of misfolded or unassembled proteins. An
early step during the assembly of a retrotranslocation
complex involves the targeting of a retrotranslocation
polypeptide to DERL1 that is not associated with the
p97 ATPase [29]. At a later stage, the p97 ATPase joins
DERL1 to form a larger retrotranslocation complex.
Similarly, in the present study, no interaction was found
between DERL1 and VIMP. The membrane protein
VIMP was shown to interact with DERL1 and recruits
Figure 4 A) RT-PCR detection of DERL1 mRNA expression in bovine corpus luteum at different stages of luteal development and B) at
different hours post-PGF2a (0, 1, 4, 8, and 12 hours). The control CL (0 h) was obtained on day 11 of the estrous cycle. Different letters
denote significant differences (p < 0.05). Data are presented as means ± SEM; n = 4 animals at each day or time point.
Figure 5 Representative Western blot analyses using
antibodies against DERL1 for protein expression in bovine
corpus luteum. DERL1 protein was observed in bovine CL at day 5,
day 11, and day 18 of the estrous cycle, with corresponding b actin
blots. The experiment was repeated using CL protein lysates from
four animals with similar results. The histogram in the lower panel
represents the quantitative expression of DERL1 during luteal
development.
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plex, to the ER for retrotranslocation of misfolded pro-
teins into the cytosol [8]. The absence of interaction
between DERL1 and VIMP would then explain why
there is no recruitment of the p97 ATPase in luteal
tissues.
Interestingly, DERL1 was found to interact with class I
MHC molecules in luteal tissues used in the present
study. A physiological role for MHC molecules in luteal
function is supported by the fact that both class I and
class II molecules are expressed by luteal cells in vivo
[10-12,30]. MHC molecules mediate the interaction
between luteal cells and T lymphocytes as a form of
cell-cell signaling to activate resident immune cells [16].
The expression of MHC molecules and the recognition
of antigenic peptides by MHC serve as a means to regu-
late T lymphocyte activation, thus controlling cytokine
production. DERL1 interacts with US11, a virally-
encoded ER protein that specifically targets MHC class I
heavy chains for export from the ER [8,31-33]. In the
present study, normal luteal tissues, analyzed at different
stages of development, showed a constant and direct
interaction between DERL1 and class I MHC. As a
DERL1-associated protein, class I MHC may represent a
factor that targets dislocation of substrates to the multi-
protein complexes. Alternatively, binding of DERL1 with
class I MHC may prevent presentation of processed
peptides to T lymphocytes, because DERL1 will control
the integrity of class I molecules, preventing activation
of T lymphocytes. Stimulation of T lymphocyte activa-
tion is dependent on the specific interaction of a T cell
receptor for antigen (TCR) on the T cell with MHC
molecules located on the surface of the target cell [34].
The outcome of binding of the TCR to the MHC mole-
cule is determined by the peptides bound to the MHC
molecules. Antigenic peptides that are presented to T
cells via MHC molecules are derived from proteins that
are proteolytically digested into short peptides prior to
binding to MHC molecules. Since antigen processing
can determine the types of peptides bound to MHC
molecules, this process can impact whether cells within
a tissue are able to activate T lymphocytes, thereby sti-
mulating an immune response, while binding of DERL1
to class I MHC would affect this process.
Conclusions
The ability of cells to dispose of misfolded proteins is
critical for cell survival. The expression of DERL1 in the
Figure 6 Co-immunoprecipitation of DERL1 and bound proteins. A) Western blotting using the pelleted precipitates from
immunoprecipitation. Blots were incubated, separately, with anti-DERL1 (1; C = DERL1 control), anti-MHC I (2), anti-VIMP (3), and anti-p97 (4)
antibodies. B) Western blotting using the supernatant collected following co-immunoprecipitation. Blots were incubated with anti- MHC I (1),
anti-VIMP (2), and anti-p97 (3) antibodies.
Ndiaye et al. Reproductive Biology and Endocrinology 2010, 8:94
http://www.rbej.com/content/8/1/94
Page 8 of 10developing follicles and in the functional CL provides
strong evidence that DERL1 might be involved in tissue
remodeling events and maintenance of function.
Although the exact function of DERL1 in the ovary is
not fully understood, its greater expression seems to be
specifically associated with active follicular growth and
early CL development and function. Furthermore, the
observation in yeast that deletion of Der1p, homolog of
mammalian DERL1, abolished degradation of the sub-
strate proteins [35] also adds more evidence that DERL1
plays a fundamental role in the cell and might be a
pivotal factor in cell survival, which is consistent with
its expression in growing follicles and functional CL.
Finally, although the retrotranslocation pathways appear
to require the function of the p97 ATPase complex [8],
the present study found no interaction betwen p97 and
DERL1 or between VIMP and DERL1. This could sug-
gest that the binding of DERL1 to MHC I would be a
regulation of MHC I molecules by DERL1 rather than a
retrotranslocation process.
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